These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 35784359)

  • 1. Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency.
    Goda V; Kriván G; Kulcsár A; Gönczi M; Tasnády S; Matula Z; Nagy G; Bekő G; Horváth M; Uher F; Szekanecz Z; Vályi-Nagy I
    Front Immunol; 2022; 13():907125. PubMed ID: 35784359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders.
    Sauerwein KMT; Geier CB; Stemberger RF; Rossmanith R; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
    J Allergy Clin Immunol; 2023 Apr; 151(4):922-925. PubMed ID: 36463978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen-Specific CD4
    Sauerwein KMT; Geier CB; Stemberger RF; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
    Front Immunol; 2022; 13():827048. PubMed ID: 35237272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
    Fidler S; Fox J; Tipoe T; Longet S; Tipton T; Abeywickrema M; Adele S; Alagaratnam J; Ali M; Aley PK; Aslam S; Balasubramanian A; Bara A; Bawa T; Brown A; Brown H; Cappuccini F; Davies S; Fowler J; Godfrey L; Goodman AL; Hilario K; Hackstein CP; Mathew M; Mujadidi YF; Packham A; Petersen C; Plested E; Pollock KM; Ramasamy MN; Robinson H; Robinson N; Rongkard P; Sanders H; Serafimova T; Spence N; Waters A; Woods D; Zacharopoulou P; Barnes E; Dunachie S; Goulder P; Klenerman P; Winston A; Hill AVS; Gilbert SC; Carroll M; Pollard AJ; Lambe T; Ogbe A; Frater J
    Clin Infect Dis; 2023 Jan; 76(2):201-209. PubMed ID: 36196614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated CD21
    Bergman P; Wullimann D; Gao Y; Wahren Borgström E; Norlin AC; Lind Enoksson S; Aleman S; Ljunggren HG; Buggert M; Smith CIE
    J Clin Immunol; 2022 May; 42(4):716-727. PubMed ID: 35290571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BNT162b2 Elicited an Efficient Cell-Mediated Response against SARS-CoV-2 in Kidney Transplant Recipients and Common Variable Immunodeficiency Patients.
    La Civita E; Zannella C; Brusa S; Romano P; Schettino E; Salemi F; Carrano R; Gentile L; Punziano A; Lagnese G; Spadaro G; Franci G; Galdiero M; Terracciano D; Portella G; Loffredo S
    Viruses; 2023 Jul; 15(8):. PubMed ID: 37632002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.
    Arroyo-Sánchez D; Cabrera-Marante O; Laguna-Goya R; Almendro-Vázquez P; Carretero O; Gil-Etayo FJ; Suàrez-Fernández P; Pérez-Romero P; Rodríguez de Frías E; Serrano A; Allende LM; Pleguezuelo D; Paz-Artal E
    J Clin Immunol; 2022 Feb; 42(2):240-252. PubMed ID: 34787773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen.
    Baek YJ; Kim WJ; Ko JH; Lee YJ; Ahn JY; Kim JH; Jang HC; Jeong HW; Kim YC; Park YS; Kim SH; Peck KR; Shin EC; Choi JY
    Vaccine; 2023 Mar; 41(10):1694-1702. PubMed ID: 36754764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.
    Pulvirenti F; Fernandez Salinas A; Milito C; Terreri S; Piano Mortari E; Quintarelli C; Di Cecca S; Lagnese G; Punziano A; Guercio M; Bonanni L; Auria S; Villani F; Albano C; Locatelli F; Spadaro G; Carsetti R; Quinti I
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations.
    Lee TH; Nam M; Seo JD; Kim H; Kim HR; Hur M; Yun YM; Moon HW
    Ann Lab Med; 2023 May; 43(3):290-294. PubMed ID: 36544341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response.
    Filippini F; Giacomelli M; Bazzani C; Fredi M; Semeraro P; Tomasi C; Franceschini F; Caruso A; Cavazzana I; Giagulli C
    BMC Med; 2023 Jun; 21(1):210. PubMed ID: 37316832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune Deficiencies.
    Pulvirenti F; Di Cecca S; Sinibaldi M; Piano Mortari E; Terreri S; Albano C; Guercio M; Sculco E; Milito C; Ferrari S; Locatelli F; Quintarelli C; Carsetti R; Quinti I
    Cells; 2022 Jun; 11(12):. PubMed ID: 35741048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
    Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
    Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes, Immunogenicity, and Safety of BNT162b2 Vaccine in Primary Antibody Deficiency.
    Milota T; Smetanova J; Skotnicova A; Rataj M; Lastovicka J; Zelena H; Parackova Z; Fejtkova M; Kanderova V; Fronkova E; Rejlova K; Sediva A; Kalina T
    J Allergy Clin Immunol Pract; 2023 Jan; 11(1):306-314.e2. PubMed ID: 36379409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy.
    Antolí A; Rocamora-Blanch G; Framil M; Mas-Bosch V; Navarro S; Bermudez C; Martinez-Yelamos S; Dopico E; Calatayud L; Garcia-Muñoz N; Hernández-Benítez LH; Riera-Mestre A; Bas J; Masuet-Aumatell C; Rigo-Bonnin R; Morandeira F; Solanich X
    Front Immunol; 2022; 13():895209. PubMed ID: 35572562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Responses 6 Months After mRNA-1273 COVID-19 Vaccination and the Effect of a Third Vaccination in Patients with Inborn Errors of Immunity.
    van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH;
    J Clin Immunol; 2023 Aug; 43(6):1104-1117. PubMed ID: 37231290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.